QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

TAK

QT44Takeda Pharmaceutical Company Limited
NYSE·Healthcare·Drug Manufacturers - Specialty & Generic·Japan
Latest market price
15.63
+0.21+1.36%
OverviewShort InterestFilings
TAKQT44Takeda Pharmaceutical Company Limited·NYSE
OverviewShort InterestFilings
15.63+1.36%
TA
Loading chart...
Screen all →
HLN+1.01%$8.96TEVA-3.32%$31.48VTRS-2.29%$15.37ELAN+3.55%$24.22RDY+1.06%$13.29RGC-18.96%$12.01LNTH+0.65%$103.86AMRX-0.43%$16.21
Snapshot
Index-P/E41.04EPS (ttm)0.41
Insider Own0.22%
Shs Outstand1.59B
Perf Week-1.51%
Market Cap49.45BForward P/E25.98EPS next Y0.60Insider Trans0.00%Shs Float-Perf Month-5.73%
Enterprise Value76.09BPEG0.53EPS next Q0.00Inst Own-Short Float-Perf Quarter-13.69%
Income1.21BP/S1.77EPS this Y-11.02%Inst Trans-Short Ratio-Perf Half Y7.57%
Sales28.00BP/B1.01EPS next Y64.89%ROA1.24%Short Interest-Perf YTD0.26%
Book/sh30.92P/C8.10EPS next 5Y25.89%ROE2.61%52W High18.90 -17.30%Perf Year4.97%
Cash/sh2.37P/FCF10.17EPS past 3/5Y-ROIC2.59%52W Low12.99 20.32%Perf 3Y-
Dividend Est.0.62 (3.97%)EV/EBITDA9.01Sales past 3/5Y2.14% 1.00%Gross Margin58.76%Volatility1.58% 1.74%Perf 5Y-
Dividend TTM0.62 (3.97%)EV/Sales2.72EPS Y/Y TTM680.62%Oper. Margin10.54%ATR (14)0.28Perf 10Y-
Dividend Ex-DateMar 31, 2026Quick Ratio0.70Sales Y/Y TTM0.49%Profit Margin4.26%RSI (14)42.43Recom2.17
Dividend Gr. 3/5Y-3.21% -6.78%Current Ratio1.27EPS Q/Q224.82%SMA20-0.67%Beta0.36Target Price-
Payout162.65%Debt/Eq0.63Sales Q/Q2.88%SMA50-5.00%Rel Volume0.81Prev Close15.42
Employees49,281LT Debt/Eq0.56EarningsJul 30SMA200-2.38%Avg Volume3.01MPrice15.63
IPO DateJan 05, 2010Option/ShortYes / YesEPS/Sales Surpr.33.33% -3.01%Net Debt/EBITDA3.15Volume2,442,724Change1.36%
Analyst Ratings
DateActionAnalystRatingTarget
Mar-16-23UpgradeB of A SecuritiesNeutral → Buy
Jul-19-22UpgradeCowen & Co.Market Perform → Outperform
Oct-07-21DowngradeMorgan StanleyOverweight → Equal Weight
Latest News
Jun-12-26
Jun-12-2610:47AM
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug DataBenzinga
Jun-11-26
Jun-11-2603:27PM
Takeda Pharmaceutical: The Downside Was ForecastableSeekingAlpha
03:27PM
Takeda Pharmaceutical: The Downside Was ForecastableSeekingAlpha
01:12PM
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' MedBenzinga
01:12PM
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' MedBenzinga
07:13AM
Takeda Says Zasocitinib (TAK-279) Demonstrated Statistical Superiority Over Deucravacitinib In Moderate-To-Severe Plaque Psoriasis PatientsBenzinga
07:13AM
Takeda Says Zasocitinib (TAK-279) Demonstrated Statistical Superiority Over Deucravacitinib In Moderate-To-Severe Plaque Psoriasis PatientsBenzinga
Jun-09-26
Jun-09-2604:31PM
FDA Accepts Review Of Takeda's Supplemental Biologics License Application For intravenous ENTYVIOBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
3/31/2026
FY 2024
3/31/2025
FY 2023
3/31/2024
FY 2022
3/31/2023
FY 2021
3/31/2022
FY 2020
3/31/2021
FY 2019
3/31/2020
FY 2018
3/31/2019
Total Revenue30,17431,69530,026
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A12,46315,51210,356
Gross Profit17,71216,18319,670
Selling, General and Administrative Excl. Other7,2517,6277,240
Research and Development4,5154,7554,786
Other Operating Expense2,639-15,399
Operating Income3,3063,8022,245
Interest Expense2,4042,515900
Unusual Expense
———
Non-Operating Income (Expense)-875-544-698
Net Income Before Taxes1,7761,8301,147
Income Taxes469479439
Consolidated Net Income1,3051,349707
Net Income From Continuing Operations1,3071,351709
Net Income1,3051,349707
EPS (Recurring)0.420.420.22
EPS (Basic, Before Extraordinaries)0.420.420.22
EPS (Diluted)0.410.420.22
EBITDA9,1509,4187,933
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio38.1243.68—
Price To Sales Ratio1.621.84—
Gross Margin58.7051.0665.51
Operating Margin10.9612.007.48
Net Margin4.324.262.35
Shares Outstanding3,1253,1503,211
Market Capitalization48,84458,338—
Operating Lease Expense
———
Insider Trading Volume
$17.82$15.76$13.70$11.64$9.58● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR